Treatable trait guided asthma management: biomarker changes and responder analysis
Aim: In a feasibility study, treatable trait (TT) guided asthma management showed clinically relevant improvements in asthma control (ACQ), quality of life (AQLQ), health status (SGRQ) and FEV1 (Fingleton et al, TSANZ ASM 2023). Changes in two type-2 (T2) biomarkers, blood eosinophils and FeNO, and associations between baseline characteristics and treatment response are described here.
Methods: Ten week two-centre open-label intervention study of patients with asthma receiving medication titrated to presence of two TTs: T2 inflammation and airflow obstruction. Participants had ACQ >1 and ≥1 exacerbation in last 12 months. Linear regression estimates changes in continuous response variables in relation to predictors.
Results: Airflow obstruction was present in 18/30 (60%) participants. Although TT intervention was associated with reduction of type-2 inflammation (Figure); change in ACQ, AQLQ, or SGRQ was not associated with baseline FEV1/FVC, log FeNO, blood eosinophils or composite T2 biomarker status. Final FEV1% predicted, adjusted for baseline, was associated with baseline airflow obstruction. Change in FEV1 predicted per unit increase FEV1/FVC ratio (95% CI), -1.69% (-2.26 to -1.13), P<0.001.
Puedes leer el artículo completo aquí: https://erj.ersjournals.com/content/62/suppl_67/PA3604
Authors: James Fingleton, Rob Mclachlan, Jenny Sparks, Richard Beasley, Alvar Agusti, Peter G Gibson, Ian Pavord, Jo Hardy, Mark Weatherall, Allie Eathorne, Vanessa M Mcdonald
European Respiratory Journal 2023 62: PA3604; DOI: 10.1183/13993003.congress-2023.PA3604
Noticias relacionadas
A Pilot Study on Proteomic Predictors of Mortality in Stable COPD
Proteomic Predictors of Mortality in Stable COPD is the objective of this pilot study. It searchs to identify proteomic markers and specific multiprotein signatures that could be useful in predicting long-term mortality
Treatable Trait Guided Asthma Management: A Feasibility Study
Protocolised treatable trait-based asthma management was acceptable to patients not under the care of a severe asthma clinic, associated with significant clinical benefit, and a full trial appears feasible.
GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry to diagnose of COPD
Siprometry to diagnose COPD: GOLD 2025 recommends using pre-BD spirometry to rule out COPD and post-BD to confirm, ensuring volume responders are not overlooked.
Artículos
Asthma
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 768973·James Fingleton, Rob Mclachlan, Jenny Sparks, Richard Beasley, Alvar Agusti, Peter G Gibson, Ian Pavord, Jo Hardy, Mark Weatherall, Allie Eathorne, Vanessa Mcdonal -Treatable trait guided asthma management: biomarker changes and responder analysis
- 768973·Xander Bertels et Al.- Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET Clinical Research Collaboration
- 769799·Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría GOLD en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en artículo original.